Duspatalin is a myotropic antispasmodic drug that has a direct effect on the smooth muscles of the gastrointestinal tract, and especially on the muscles of the colon. Due to these properties, the drug is used for functional disorders of the gastrointestinal tract.
It has no anticholinergic effect, does not affect the normal intestinal motility.
Release form and composition
Duspatalin is available in the form of enteric-coated tablets and sustained-release capsules.
The active ingredient of the drug is mebeverine hydrochloride, in one tablet it contains 135 mg, in one capsule - 200 mg.
Excipients included in tablets:
- Magnesium stearate;
- Carnauba wax;
- Potato starch;
- Lactose monohydrate.
Additional components included in the capsules:
- Titanium dioxide (E171);
- Magnesium stearate;
- Glycerol triacetate;
- Polyacrylate dispersion;
- Methacrylate copolymer dispersion;
Indications for use
Duspatalin is prescribed for symptomatic treatment:
- Irritable bowel syndrome (to eliminate discomfort, dysfunction, abdominal pain and cramps);
- Spasms of the digestive tract organs of various origins, including those caused by organic diseases;
- Biliary and intestinal colic.
Children over 12 years old in the form of tablets, the drug can be given for functional disorders of the gastrointestinal tract, accompanied by abdominal pain.
The main contraindication to the use of Duspatalin in both dosage forms is a known hypersensitivity to mebeverin or any excipient.
Duspatalin tablets as additional components, including, contain sucrose and lactose. Therefore, in this form, the drug is not prescribed for lactase deficiency, hereditary intolerance to galactose, glucose-galactose malabsorption.
In capsules, the drug is not prescribed to children and adolescents under the age of 18 years, due to the high content of the active substance. In tablets, medicine can be given to children not younger than 12 years old.
During the testing of mebeverin in animals, no teratogenic effect was detected. However, clinical data on the safety of taking Duspatalin during pregnancy is not enough. For this reason, pregnant women are prescribed the drug only after a thorough assessment of possible risks.
Dosing and Administration
The drug is intended for oral administration. Both tablets and capsules should be taken approximately 20 minutes before a meal:
- Tablets - 1 pc. three times a day;
- Capsules - 1 pc. twice a day.
If for some reason the patient missed another dose, it is prohibited to increase the next dose.
According to clinical studies, this drug has no serious side effects. It is important to note that the incidence of adverse reactions when taking Duspatalin and placebo is practically no different.
Reports that the drug may have side effects were received in the post-marketing period. However, the available data are not sufficient for a reliable estimate of the frequency of cases.
So, according to reviews of the drug, Duspatalin can cause allergic reactions, manifested by urticaria, itching, exanthema and angioedema. In addition, there is evidence of isolated cases of anaphylactic reactions due to intolerance to the components of the drug.
When you receive a dose that is much higher than the recommended therapeutic, it is possible to increase the excitability of the central nervous system. There are several cases of overdose of mebeverin, when a person intentionally or accidentally took a high dosage of the drug. However, any undesirable symptoms were mostly absent altogether, and those that appeared were minor and, as a rule, quickly reversible. They were neurological or cardiovascular. However, without the agreement of the doctor, you should not exceed the dose.
When taking mebeverin in therapeutic doses, the substance does not penetrate into breast milk, so the medicine can be prescribed during lactation.
Studies on the pharmacological compatibility of Duspatalin with other drugs have not been conducted, and therefore the possibility of the simultaneous use of any other drug must be clarified with the doctor.
No special studies have been conducted on the effect of mebeverin on visual acuity, the rate of physical and mental reactions. However, based on the properties of Duspatalin and the post-marketing experience of its use, it can be argued that the drug does not adversely affect the ability to perform potentially hazardous types of work and drive a car.
With the same active ingredient are produced drugs Meverin, Mebsin retard, Moreaze Wed, Niaspam, Spareks.
The following drugs also belong to the group of myotropic antispasmodics: Avisan, Altalex, Bendazol, Halidor, Dibazol, Ditsetel, Driptan, Droverin, Drotaverin, Kellin, Librax, Neobutin, No-shpa, Novitropan, Oxybutin, Papaverin, Platifiln, Oxybutin, Papaverin, Platyphyln, Nephutin, Nooputin, Plithylin, Plithyln, Plithyln, Plithyln, Plithyln, Plithyln, Plithyln, Plithyln, Plithyln, Pythyphyln, Plithyln, Ophylsil, Plathiln, Ophthropyne, Dyphalonum Spa, Spasmol, Spasmomen, Spasmonet, Spasmotsistenal, Spakovit, Spareks, Trigan, Trimspa, Trimedat, Trimedat Valens, Fennel fruits, Cistenal, Cistrin, Enablex.
Terms and conditions of storage
Duspatalin for sale without a prescription. Store the drug, according to the instructions, it is necessary in a darkened and protected from moisture penetration. The recommended storage temperature is 5-25 ºC. If these conditions are met, the shelf life of the capsules is 3 years, tablets - 5 years.